CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLABO19

Thyroid Disease Testing

BCBS Oklahoma clinical payment and coding policy defining reimbursement criteria for thyroid function and antibody testing across indications (hypothyroidism, hyperthyroidism, pregnancy, high-risk/asymptomatic high-risk, monitoring during therapy, special populations). It specifies reimbursable and non-reimbursable tests and related procedure codes.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyThyroid Disease Testing

Policy CodePolicy CPCPLABO19

Change TypeNew policy; reimbursement clarified

Effective DateJun 15, 2023

Next Review Date

Key ActionProviders must submit accurate documentation and clinical justification for testing consistent with the listed reimbursable indications; BCBSOK may request additional documentation during claim review.

POLICY UPDATE CHANGES

New policy implemented with literature review and reimbursement information clarified.

3Core reimbursable tests highlighted (TSH, fT4, T3 variants)

4Pregnancy-specific recommendations (frequency/assays)

4Explicit non-reimbursable tests (rT3, T3 uptake, total T4, T3 for dosing)

Coverage Summary

BCBS Oklahoma clinical payment and coding policy (Policy Number: CPCPLABO19) defines reimbursement criteria for thyroid function and antibody testing across multiple indications including hypothyroidism, hyperthyroidism, pregnancy, high‑risk/asymptomatic high‑risk individuals, monitoring during therapy, and special populations. The policy is CURRENT and was approved April 12, 2023 with a plan effective date of June 15, 2023.

Medical-Necessity Criteria

Reimbursable Thyroid Function Testing - General

Thyroid function testing may be reimbursable when specific clinical indications or monitoring needs are met.

Initial/evaluation testing for hypothyroidism

Tests: TSH to confirm or rule out primary hypothyroidism
Tests: Free T4 (fT4) as a follow up to abnormal TSH findings
Tests: TSH and fT4 in cases of suspected secondary (central) hypothyroidism

Monitoring treated hypothyroidism

Frequency: For individuals being treated for hypothyroidism, monitoring with TSH and fT4 testing every 6 weeks upon dosage change
Frequency: Annual TSH and fT4 testing in stable individuals

Initial/evaluation testing for hyperthyroidism

Tests: TSH to confirm or rule out overt hyperthyroidism
Tests: Free T4 as a follow up to abnormal TSH findings
Tests: Total T3 (TT3) or free T3 (fT3) to confirm a diagnosis of hyperthyroidism

Monitoring treated hyperthyroidism

Frequency: Repeat testing of TSH and fT4 every 6-8 weeks in patients being treated for hyperthyroidism
Use: Free T4 to distinguish between overt and subclinical hyperthyroidism

Asymptomatic individuals at high risk for thyroid disease

High-risk criteria: Personal or family history of thyroid dysfunction; Prescribed drugs that can interfere with thyroid function; Personal or family history of type 1 diabetes or other autoimmune disorder
Monitoring frequency: Annual monitoring (after first year) and monitoring when dosage or medication changes

Individuals capable of becoming pregnant

Indications: Undergoing evaluation for infertility; If symptoms consistent with thyroid dysfunction develop; For pregnant or postpartum individuals with symptoms, TSH and fT4 testing once every 4 weeks may be reimbursable
See pregnancy-specific notes for assay and frequency details

Special and other reimbursable indications

Disease/neoplasm and therapies: Individuals with disease or neoplasm of the thyroid or other endocrine glands; Individuals undergoing immune reconstitution therapy (IRT); Individuals with HIV undergoing HAART; Individuals following allogeneic BMT or HSCT; Individuals with active relapsing remitting MS undergoing alemtuzumab therapy
Mitochondrial disease: Individuals diagnosed with primary mitochondrial disease: annual screening of TSH and fT4
Central hypothyroidism: Individuals suspected of central hypothyroidism
Pediatrics: Pediatric individuals diagnosed with short stature; Pediatric individuals with clinical finding of failure-to-thrive

Antibodies, cancer surveillance, and specialty tests

Antibody testing: For individuals with hypothyroidism or hyperthyroidism: testing for thyroid antibodies may be reimbursable once every three years
Thyroid cancer surveillance: Individuals with thyroid cancer: testing for serum thyroglobulin and/or thyroglobulin antibody (Tg-Ab) levels for detection of tumor recurrence, post-surgical evaluation, surveillance, and maintenance for differentiated thyroid carcinomas
Other evaluative tests: For evaluation of cause of hyperthyroidism or hypothyroidism: testing for thyrotropin-releasing hormone (TRH) or thyroxine-binding globulin (TBG) may be reimbursable

Top-level selection: One of the following indications must be met for reimbursement

Not Reimbursable Testing / Exclusions

Tests and situations that are not reimbursable unless specifically listed above.

General exclusions: For all other situations not mentioned above; testing of reverse T3, T3 uptake and total T4 is not reimbursable

T3 testing exclusions: For the assessment of hypothyroidism, measurement of total T3 (TT3) and/or free T3 (fT3) is not reimbursable; To assess levothyroxine dose in hypothyroid individuals, measurement of total or free T3 level is not reimbursable

Screening exclusions: For asymptomatic nonpregnant individuals, testing for thyroid dysfunction during a general exam without abnormal findings is not reimbursable

Pregnancy-specific testing notes

Special considerations for thyroid testing during pregnancy.

Laboratory requirements in pregnancy: Measurement of hormone levels should only be performed at labs that have trimester specific normal ranges for their assay(s)

Assay preference and alternatives: fT4 is preferred; TT4 may be useful if TSH and fT4 results are discordant or when trimester specific normal ranges for fT4 are unavailable

Pregnancy/postpartum hyperthyroidism: For pregnant or postpartum individuals diagnosed with hyperthyroidism, TT4, Tg-Ab, TRab, and TPOAb may be reimbursable

Frequency for symptomatic pregnant/postpartum individuals: For individuals who are pregnant or who are postpartum and who have symptoms of thyroid dysfunction, TSH and fT4 testing (once every 4 weeks) may be reimbursable

Background

Background: BCBSOK implemented lab management reimbursement criteria for thyroid testing and monitoring and references multiple guideline and literature sources to support clinical indications and limits. The policy lists example procedure codes (not exhaustive) and instructs providers to use valid HIPAA‑approved code sets and submit clinical documentation to support reimbursable testing.

Implementation details and guideline references: The policy cites practice guidelines and clinical literature (see referenced sources) and was updated with a literature review on 6/15/2023, with reimbursement information and references revised for clarity.

Pregnancy and special populations: The policy emphasizes pregnancy‑specific considerations (labs must have trimester‑specific normal ranges; fT4 preferred with TT4 acceptable when trimester‑specific fT4 ranges are unavailable) and includes special population guidance (examples: post‑transplant, immune reconstitution therapy, HAART, mitochondrial disease, pediatric short stature, infertility, history of pregnancy loss).

Reimbursable vs non‑reimbursable: The policy explicitly clarifies reimbursable assays, indications and frequencies (for example, TSH, fT4 and selected antibody testing with specified monitoring intervals) and enumerates non‑reimbursable tests and scenarios (for example, reverse T3, T3 uptake, total T4 in many contexts, and T3 testing for levothyroxine dose assessment), as well as frequency limits for antibody testing and pregnancy monitoring.

Definitions

fT4Free thyroxine measurement used for follow-up to abnormal TSH and monitoring.

TSHThyroid stimulating hormone used to screen for primary hypo- or hyperthyroidism.

84482	Thyroid stimulating hormone (TSH)
86376	Thyroid peroxidase (TPO) antibody
86800	Thyroid-related assay (code listed in document)

OpenPayer

Thyroid Disease Testing

Coverage Summary

Medical-Necessity Criteria

Coding

Provider Actions / Billing Requirements

Background

Revision History